NCHR writes on behalf of five nonprofit health organizations that have examined issues pertaining to primary prevention of breast cancer for decades and urge the USPSTF to consider revising their current recommendations on breast cancer risk reducing drugs.
Read More »On Medical Treatments & Products
Testimony at FDA on Sotagliflozin to Help Manage Type 1 Diabetes
January 17, 2019. Just providing new treatment options is not enough. New treatments must provide a real tangible benefit for patients without too much risk.
Read More »NCHR Testimony at the FDA on Optimizer for Heart Failure
December 4, 2018. We all want to help these patients, but new treatments need to provide a real benefit. The questions that we need to answer are does this device help patients and should patients continue to have the option of receiving an experimental treatment as part of a clinical trial, or should they pay for an experimental treatment that has been described as a breakthrough?
Read More »Is TMS Proven Effective for Depression?
This report will examine how TMS became a frequently used treatment for depression in the United States despite what the research of the last decade shows about its very questionable effectiveness.
Read More »NCHR Testimony on Antidepressant Brexanolone for Postpartum Depression
National Center for Health Research testifies against the approval of a new first of its kind drug for postpartum depression called Brexanolone.
Read More »